N
Nimbus Therapeutics
Applying deep computational chemistry expertise to create novel small molecule therapeutics
About Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company focused on designing small molecule therapeutics to address significant challenges in drug development. The company operates in the pharmaceutical and biotechnology market, serving patients with unmet medical needs. Nimbus employs a unique collective expertise to push the boundaries of drug discovery and development. The business model revolves around research and development of breakthrough medicines, backed by substantial investments from prominent life science investors like Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, and Lightstone Ventures. Nimbus generates revenue through partnerships, licensing agreements, and milestone payments from pharmaceutical companies. The company has secured multiple rounds of financing, including a $24 million Series A in 2011, a $43 million Series B in 2015, and an additional $65 million in 2018.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- Cambridge, United States
- Employees
- 101
- Open positions
- None listed
- Dealroom signal
- 38.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, DNA, Genetics and genomics, Genome Engineering, Rumoured $1B, Biotech and Pharma, Techbio, Hard Tech, DT and LS
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2023 | $210M | $840M | Atlas Venture · Lightstone Ventures · RA Capital Management · Pfizer Ventures | ↗ |
| ACQUISITIONOther financing | Dec 2022 | $0 | — | Takeda | ↗ |
Growth signals
Latest recorded traffic for Nimbus Therapeutics is 12K monthly website visits, up 20% over the last three months. Nimbus Therapeutics's team grew 3.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Atlas Venture
Bill Gates
Richard Friesner
Series A4 investors entered at this stage
- PVPfizer Ventures
SR One
Lilly Ventures
Lightstone Ventures
Series B and later10 investors entered at this stage
BVF Partners
Commodore Capital
RA Capital Management
Logos Capital
Access Biotechnology
Surveyor Capital
SV Health Investors
Bain Capital Life Sciences
GV- GFGates Frontier
Other known investors1 additional known investor
Takeda
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nimbus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nimbus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.